blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP0526608

EP0526608 - THERAPEUTIC AGENTS FOR THE TREATMENT OF MULTIDRUG RESISTANCE TO CANCERS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  24.10.1997
Database last updated on 03.10.2024
Most recent event   Tooltip14.03.2003Change - lapse in a contracting state
Updated state(s): MC		published on 02.05.2003  [2003/18]
Applicant(s)For all designated states
DEBIOPHARM S.A.
15-17 rue des Terraux
CH-1003 Lausanne / CH
For all designated states
PATRINOVE
39, rue du Lieutenant-Colonel-Prévost
69006 Lyon / FR
For all designated states
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
101, rue de Tolbiac
75654 Paris Cédex 13 / FR
[N/P]
Former [1993/06]For all designated states
DEBIOPHARM S.A.
15-17 rue des Terraux
CH-1003 Lausanne / CH
For all designated states
PATRINOVE
39, rue du Lieutenant-Colonel-Prévost
F-69006 Lyon / FR
For all designated states
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
101, rue de Tolbiac
F-75654 Paris Cédex 13 / FR
Inventor(s)01 / CHAUFFERT, Bruno
57, rue d'Auxonne
F-21000 Dijon / FR
02 / GENNE, Philippe
6, Grand Rue
F-21121 Ahuy / FR
03 / GUTIERREZ, Gilles
39, rue Lt.-Colonel-Prévost
F-69006 Lyon / FR
04 / MAUVERNAY, Rolland-Yves
15-17, rue des Terreaux
CH-1003 Lausanne / CH
[1993/06]
Representative(s)Micheli & Cie SA
Rue de Genève 122
Case Postale 61
1226 Genève-Thônex / CH
[N/P]
Former [1993/22]Micheli & Cie
Rue de Genève 122, Case Postale 61
CH-1226 Genève-Thonex / CH
Former [1993/06]Vuille, Roman (CH)
Avenue Nestlé 55
CH-1800 Vevey / CH
Application number, filing date92905338.724.02.1992
[1993/06]
WO1992EP00408
Priority number, dateCH1991000057625.02.1991         Original published format: CH 57691
CH1991000352202.12.1991         Original published format: CH 352291
[1993/06]
Filing languageFR
Procedural languageFR
PublicationType: A1 Application with search report
No.:WO9214467
Date:03.09.1992
Language:FR
[1992/23]
Type: A1 Application with search report 
No.:EP0526608
Date:10.02.1993
Language:FR
The application published by WIPO in one of the EPO official languages on 03.09.1992 takes the place of the publication of the European patent application.
[1993/06]
Type: B1 Patent specification 
No.:EP0526608
Date:18.12.1996
Language:FR
[1996/51]
Search report(s)International search report - published on:EP03.09.1992
ClassificationIPC:A61K31/49
[1993/06]
CPC:
A61K31/49 (EP,US); A61P35/00 (EP); A61P43/00 (EP)
Designated contracting statesAT,   BE,   CH,   DE,   DK,   ES,   FR,   GB,   GR,   IT,   LI,   LU,   MC,   NL,   SE [1993/06]
TitleGerman:Therapeutische Mittel für die Behandlungder Resistenz gegen Arzneimittel bei Krebs[1993/06]
English:THERAPEUTIC AGENTS FOR THE TREATMENT OF MULTIDRUG RESISTANCE TO CANCERS[1993/06]
French:AGENTS THERAPEUTIQUES POUR LE TRAITEMENT DE LA RESISTANCE MULTIDROGUE DE CANCERS[1993/06]
Entry into regional phase21.10.1992National basic fee paid 
21.10.1992Designation fee(s) paid 
21.10.1992Examination fee paid 
Examination procedure21.10.1992Examination requested  [1993/06]
09.03.1995Despatch of a communication from the examining division (Time limit: M06)
07.08.1995Reply to a communication from the examining division
12.10.1995Despatch of a communication from the examining division (Time limit: M02)
25.11.1995Reply to a communication from the examining division
18.04.1996Despatch of communication of intention to grant (Approval: Yes)
17.06.1996Communication of intention to grant the patent
16.08.1996Fee for grant paid
16.08.1996Fee for publishing/printing paid
Opposition(s)19.09.1997No opposition filed within time limit [1997/50]
Fees paidRenewal fee
20.01.1994Renewal fee patent year 03
19.01.1995Renewal fee patent year 04
18.01.1996Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT18.12.1996
DK18.12.1996
GR18.12.1996
BE28.02.1997
LU28.02.1997
MC31.08.1997
[2003/18]
Former [2003/17]AT18.12.1996
DK18.12.1996
GR18.12.1996
BE28.02.1997
LU28.02.1997
MC01.09.1997
Former [2000/05]AT18.12.1996
DK18.12.1996
GR18.12.1996
BE28.02.1997
LU28.02.1997
MC31.08.1997
Former [1998/15]AT18.12.1996
DK18.12.1996
BE28.02.1997
MC31.08.1997
Former [1998/11]AT18.12.1996
BE28.02.1997
MC31.08.1997
Former [1998/10]AT18.12.1996
BE28.02.1997
Former [1997/42]AT18.12.1996
Cited inInternational search[Y]  - Molecular Pharmacology, vol. 33, no. 4, avril 1988, (US), J.M. ZAMORA et al.: "Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells", pages 454-462, voir abrégé; pages 457-458
 [Y]  - Proceedings of the 77th Annual Meeting of the American Association for Cancer Research, Los Angeles, CA, 7-10 mai 1986, vol. 27, J.M. ZAMORA et al.: "Potentiation of Vinca alkaloid (VA) cytotoxicity by quinolines, acridines, indole alkaloids and aromatic amines", page 395, abrégé no. 1567, voir le document en entier
 [Y]  - International Journal of Cancer, vol. 46, no. 1, 15 juillet 1990, (Lausanne, CH), J.F. ELIASON et al.: "Human multi-drug-resistant cancer cells exhibit a high degree of selectivity for stereoisomers of verapamil and quinidine", pages 113-117, voir le document en entier
 [X]  - Tetrahedron Letters, vol. 27, no. 49, 1986, (GB), R.T. BROWN et al.: "Stereospecific synthesis of erythro Cinchona alkaloids from secologanin", pages 6005-6008, voir pages 6005-6006
 [X]  - H. RIMPLER et al.: "Pharmazeutische Biologie II. Biogene Arzneistoffe", 1990, pages 437-440: "Cinchonae cortex", Georg Thieme Verlag, Stuttgart, DE, voir pages 439-440
 [X]  - J.E.F. REYNOLDS et al.: "Martindale - The Extra Pharmacopoeia", 28 édition, 1982, page 1378, The Pharmaceutical Press, Londres, GB, voir monographie no. 7786-v: "Hydroquinidine hydrochloride"
 [X]  - S. BUDAVARI et al.: "The Merck Index", 11 édition, 1989, page 356, Merck & Co., Rahway, NJ, US, voir monographie no 2289: "Cinchonine"
 [X]  - S. BUDAVARI et al.: "The Merck Index", 11 édition, 1989, page 762, Merck & Co., Rahway, NJ, US, voir monographie no. 4736: "Hydroquinidine"
 [Y]  - Ann. Ist. Super. Sanita, vol. 21, no. 3, 1985, (IT), D.C. WARHURST: "New drugs and their potential use against drug-resistant malaria", pages 327-336, voir abrégé; pages 328-329
 [Y]  - Nature, vol. 345, 17 mai 1990, (Londres, GB), C. NEWBOLD: "The path of drug resistance", pages 202-203, voir page 202
 [Y]  - Annals of Tropical Medicine and parasitology, vol. 69, no. 4, décembre 1975, (Liverpool, GB), N.M. MATTOCK et al.: "The experimental chemotherapy of leishmaniasis. III. Detection of antileishmanial activity in some new synthetic compounds in a tissue culture model", pages 449-462, voir page 456
 [X]  - Therapie, vol. 43, no. 4, juin/juillet 1988, B. FLOUVAT et al.: "Métabolites de la dihydroquinidine observés après administration à l'homme d'une formulation à libération prolongée", pages 255-261, voir l'abrégé
 [X]  - J. Chem. Soc. Perkin Trans. I, 1988, M. IHARA et al.: "Total synthesis of hydrocinchonidine and hydrocinchonine via photo-oxygenation of an indole derivative", pages 1277-1281, voir l'abrégé; schémas 1-4
Examination   - Cancer Research 52, 1992, pages 2797 - 2801
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.